Kurzfassung

A randomized, double-blind, double-dummy, multicenter study to assess the study, tolerability and long-term efficacy of intravenous (10mg/kg) and subcutaneou (300mg) secukinumab in subjects with moderate to severe chronic plaque-type psoriasis who are partial responder to secukinumab